SynthesisInternational journal of biological sciences2022
A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.
Synthesis in International journal of biological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- SARS-CoV-2 pathophysiology and post-vaccination severity: a systematic review.Immunologic research · 2024Pooled it
- Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review.International journal of immunopathology and pharmacologyPooled it
- A High-Throughput Platform for Rapid Adaptation of DNA Aptamers to SARS-CoV-2 Evolution.bioRxiv : the preprint server for biology · 2026Article
- An analytic approach considering two temporal mechanisms driving breakthrough viral infections after vaccination.Vaccine · 2025Article
- SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies.International journal of molecular sciences · 2025Review
- Review
- Expression, purification and immunogenicity analyses of receptor binding domain protein of severe acute respiratory syndrome coronavirus 2 from delta variant.Veterinary research forum : an international quarterly journal · 2024Article
- Factors Associated to Community Practices Toward the COVID-19 Pandemic: A Cross-Sectional Study in Indonesia.Journal of multidisciplinary healthcare · 2024Article
- Correlative analysis of wastewater trends with clinical cases and hospitalizations through five dominant variant waves of COVID-19.ACS ES&T water · 2023Article
- Article
- Protection against Severe Illness versus Immunity-Redefining Vaccine Effectiveness in the Aftermath of COVID-19.Microorganisms · 2023Review
- The Impact of Vaccination Among Hospitalized Patients with the Diagnosis of COVID-19.Infectious diseases & clinical microbiology · 2023Article
- Association Between Cycle Threshold Value and Vaccination Status Among Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Cases in Ontario, Canada, in December 2021.Open forum infectious diseases · 2023Article
- Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report.Journal of medical case reports · 2023Article
- Pulmonary computed tomographic manifestations of COVID-19 in vaccinated and non-vaccinated patients.Scientific reports · 2023Article
- Analysis of the Virus SARS-CoV-2 as a Potential Bioweapon in Light of International Literature.Military medicine · 2023Article
- The causal effect of physical activity intensity on COVID-19 susceptibility, hospitalization, and severity: Evidence from a mendelian randomization study.Frontiers in physiology · 2023Article
- Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.Journal of infection and public health · 2023Review
- Article
- Exploring the experience of developing COVID-19 vaccines in Iran.Clinical and experimental vaccine research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines are proving to be highly effective in controlling hospitalization and deaths associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as shown by clinical trials and real-world evidence. However, a deadly second wave of coronavirus disease 2019 (COVID-19), infected by SARS-CoV-2 variants, especially the Delta (B.1.617.2) variant, with an increased number of post-vaccination breakthrough infections were reported in the world recently. Actually, Delta variant not only resulted in a severe surge of vaccine breakthrough infections which was accompanied with high viral load and transmissibility, but also challenged the development of effective vaccines. Therefore, the biological characteristics and epidemiological profile of Delta variant, the current status of Delta variant vaccine breakthrough infections and the mechanism of vaccine breakthrough infections were discussed in this article. In addition, the significant role of the Delta variant spike (S) protein in the mechanism of immune escape of SARS-CoV-2 was highlighted in this article. In particular, we further discussed key points on the future SARS-CoV-2 vaccine research and development, hoping to make a contribution to the early, accurate and rapid control of the COVID-19 epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.